Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale

NEW YORK, September 12, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), United Therapeutics Corporation (NASDAQ: UTHR) and Brookdale Senior Living, Inc. (NYSE: BKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6426-100free.

--
Gilead Sciences, Inc. Research Reports
On September 8, 2014, Gilead Sciences, Inc. (Gilead) announced the results from its AMBITION study, a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in patients with pulmonary arterial hypertensION, which was conducted in collaboration with GlaxoSmithKline (GSK). The Company informed that in AMBITION, first-line treatment of pulmonary arterial hypertension (PAH) with the combination of ambrisentan 10 mg and tadalafil 40 mg reduced the risk of clinical failure by 50% compared to the pooled ambrisentan and tadalafil monotherapy arm (hazard ratio = 0.502; 95 percent CI: 0.348, 0.724; p=0.0002). The Company plans to submit the AMBITION data in a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration by the end of 2014. The full research reports on Gilead are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/GILD/report.pdf

--
AbbVie Inc. Research Reports
On September 3, 2014, AbbVie Inc. (AbbVie) and Infinity Pharmaceuticals, Inc. (Infinity) jointly announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. Under the terms of the agreement, Infinity will receive an upfront payment of $275 million and up to $530 million in additional payments for the achievement of development, regulatory and commercial milestones. In the U.S., both companies will jointly commercialize duvelisib, while the profits will be shared equally. Outside the U.S., AbbVie will be responsible for the conduct and funding of commercialization of duvelisib, and Infinity will receive tiered double-digit royalties on net product sales. Michael Severino, M.D., AbbVie Executive Vice President and Chief Scientific Officer, said, "The addition of duvelisib will complement AbbVie's emerging oncology pipeline and expand our research into combination therapies to generate improved outcomes for cancer patients. We look forward to working with Infinity to bring duvelisib to patients worldwide." The full research reports on AbbVie are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/ABBV/report.pdf

--
Pfizer Inc. Research Reports
On August 28, 2014, Pfizer Inc. (Pfizer) announced that the Company's investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The Company informed that the C. difficile vaccine, which is designed to prevent C. difficile-associated disease such as life-threatening diarrhea and pseudomembranous colitis, is in its Phase 2 clinical development. Dr. Emilio Emini, Senior Vice President of Vaccine Research and Development for Pfizer, said, "No vaccine is currently available to prevent the infection-associated disease. In the United States alone, there are approximately 250,000 cases of C. difficile-associated disease, resulting in approximately 14,000 deaths each year." The full research reports on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/PFE/report.pdf

--
United Therapeutics Corporation Research Reports
On September 9, 2014, shares in United Therapeutics Corporation (United Therapeutics) gained 2.10% to end the trading session at $117.34. Shares in United Therapeutics opened the session at $114.45 and oscillated in the range of $114.36 - $121.88. A total of 2.37 million shares changed hands during the session, higher than its 30-day average volume of 0.84 million shares. Over the past one month, the stock has skyrocketed 32.23%. On August 29, 2014, United Therapeutics reported that the U.S. District Court for the District of New Jersey has ruled in its favor in the Company's case against Sandoz, Inc. regarding United Therapeutics' Remodulin® product. Following the news, the Company's stock surged 28.51% to end the session at $117.83 on August 29, 2014. The full research reports on United Therapeutics are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/UTHR/report.pdf

--
Brookdale Senior Living, Inc. Research Reports
On September 2, 2014, Brookdale Senior Living, Inc. (Brookdale) and HCP jointly announced the closing of their previously disclosed multiple-element transaction, which includes the creation of a $1.2 billion strategic joint venture initially owning a portfolio of 14 entry fee CCRCs; and amendments to the triple-net leases on 202 HCP-owned senior housing communities formerly operated by Emeritus Corporation, which was acquired by Brookdale in July 2014. In addition, parallel with the closing, HCP invested $324 million of cash into the CCRC joint venture, which was used to acquire four communities representing four of the 14 campuses that initially constitute the venture. Andy Smith, Brookdale's CEO, said, "We are very excited about broadening our relationship with HCP through both the merger with Emeritus and this transaction, which creates attractive opportunities to build shareholder value for Brookdale and HCP." The full research reports on Brookdale are available to download free of charge at:

http://www.analystsreview.com/Sep-12-2014/BKD/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review